After meeting with Biogen's management, RBC Capital thinks the stock should trade up into the AP/PD conference and should rise over the course of 2015. The firm believes that the company's BIIB-037 is the best in class Alzheimer's treatment, making the stock attractive to investors. RBC keeps an Outperform rating on the shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here